Physician

Michelle Elizabeth Melisko, MD

According to 2025 Medicare claims, Michelle Melisko, MD (NPI: 1306803812) practices internal medicine in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Mateo, CA. This provider's primary affiliated billing organization is UCSF MEDICAL GROUP BUSINESS SERVICES (NPI: 1477624104; TIN: 943281660) and primary practice location at 94010-4145.

Melisko's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 152 traditional Medicare patients, billed 13,253 HCPCS/CPT codes, and received $339,592 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 581 prescription claims across 109 beneficiaries totaling $935,886 in drug costs, led by Verzenio (Abemaciclib). DME data shows 47 claims. Open Payments data shows 7 records totaling $44,489. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $44,342 to $339,592. Similarly, Part D prescription costs have risen steadily, from $250,029 to $935,886. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $518 to $10,306.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	194	515	$44,342
2016	163	483	$41,927
2017	128	282	$25,588
2018	97	286	$25,673
2019	92	239	$22,171
2020	90	300	$29,606
2021	119	447	$49,002
2022	155	3,775	$133,003
2023	150	12,852	$350,199
2024	152	13,253	$339,592

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	87	646	$250,029
2016	88	587	$409,436
2017	97	575	$436,051
2018	83	560	$375,564
2019	101	618	$565,728
2020	99	561	$664,032
2021	93	493	$231,559
2022	96	598	$456,925
2023	107	550	$680,006
2024	109	581	$935,886

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	90	$56,386
2016	N/R	62	$35,876
2017	N/R	32	$13,125
2018	N/R	12	$3,095
2019	N/R	12	$2,597
2020	N/R	11	$1,089
2021	N/R	31	$1,602
2022	N/R	54	$1,845
2023	N/R	88	$23,659
2024	N/R	47	$1,475

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	14	14	$161
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	148	436	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	53	66	$90
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	51	105	$28
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	82	269	$15

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	26	728	$388,979
Ibrance	Palbociclib	18	504	$274,667
Letrozole	Letrozole	130	9,330	$4,615
Exemestane	Exemestane	30	1,860	$4,019
Anastrozole	Anastrozole	102	7,680	$2,375

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	25	$1,061
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	22	$414

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$4,096	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$40,393	PUMA BIOTECHNOLOGY, INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michelle Elizabeth Melisko, MD?

Tedicare shows public-source Medicare data for Michelle Elizabeth Melisko, MD (NPI 1306803812), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michelle Elizabeth Melisko, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michelle Elizabeth Melisko, MD?

Michelle Elizabeth Melisko, MD is linked to UCSF MEDICAL GROUP BUSINESS SERVICES (billing NPI 1477624104) in the available physician profile data.

Does Michelle Elizabeth Melisko, MD have Open Payments data?

Michelle Elizabeth Melisko, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.